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Abstract
Introduction: Emerging HIV epidemics have been documented among people who inject drugs (PWID) in the Middle East and
North Africa (MENA). This study estimates the HIV incidence among PWID due to sharing needles/syringes in MENA. It also
delineates injecting drug use role as a driver of the epidemic in the population, and estimates impact of interventions.
Methods: A mathematical model of HIV transmission among PWID was applied in seven MENA countries with sufficient and
recent epidemiological data and HIV prevalence ≥1% among PWID. Estimations of incident and/or prevalent infections among
PWID, ex-PWID and sexual partners of infected current and ex-PWID were conducted.
Results: The estimated HIV incidence rate for 2017 among PWID ranged between 0.7% per person-year (ppy) in Tunisia and
7.8% ppy in Pakistan, with Libya being an outlier (24.8% ppy). The estimated number of annual new infections was lowest in
Tunisia (n = 79) and Morocco (n = 99), and highest in Iran and Pakistan (approximately n = 6700 each). In addition, 20 to
2208 and 5 to 837 new annual infections were estimated across the different countries among sexual partners of PWID and
ex-PWID respectively. Since epidemic emergence, the number of total ever acquired incident infections across countries was
706 to 90,015 among PWID, 99 to 18,244 among sexual partners of PWID, and 16 to 4360 among sexual partners of ex-
PWID. The estimated number of prevalent infections across countries was 341 to 23,279 among PWID, 119 to 16,540 among
ex-PWID, 67 to 10,752 among sexual partners of PWID, and 12 to 2863 among sexual partners of ex-PWID. Increasing
antiretroviral therapy (ART) coverage to the global target of 81% – factoring in ART adherence and current coverage – would
avert about half of new infections among PWID and their sexual partners. Combining ART with harm reduction could avert
over 90% and 70% of new infections among PWID and their sexual partners respectively.
Conclusions: There is considerable HIV incidence among PWID in MENA. Of all new infections ultimately due to injecting
drug use, about 75% are among PWID and the rest among sexual partners. Of all prevalent infections ultimately attributed to
injecting drug use as epidemic driver, about half are among PWID, 30% among ex-PWID and 20% among sexual partners of
PWID and ex-PWID. These findings call for scale-up of services for PWID, including harm reduction as well as testing and
treatment services.
Keywords: HIV; people who inject drugs; Middle East and North Africa; incidence; prevalence; mathematical modelling;
intervention
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1 | INTRODUCTION
As part of the global commitment to end the AIDS epi-
demic by 2030, the Joint United Nations Programme on
HIV/AIDS (UNAIDS) stipulated the ambitious fast-tracking
agenda including a “90-90-90” target calling to diagnose
90% of people living with HIV/AIDS (PLHIV), provide
antiretroviral therapy (ART) for 90% of those diagnosed,
and achieve viral suppression for 90% of those treated [1].
Also, on the fast track agenda is to reduce the number of
new infections to below 500,000 by 2020 [2]. With gaps
persisting along this HIV cascade, the UN General Assembly
agreed in 2016 that staying on the Fast-Track to ending
AIDS by 2030 would only be possible if key populations
(KPs) at higher risk of infection have access to comprehen-
sive prevention services [3].
Mumtaz GR et al. Journal of the International AIDS Society 2018, 21:e25102
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25102/full | https://doi.org/10.1002/jia2.25102
1
The Middle East and North Africa (MENA), which we define
to include 24 countries from Morocco in the West to Afghani-
stan and Pakistan in the East, is one of few regions where the
number of new HIV infections is increasing [3]. The vast
majority of these infections seem to be occurring among KPs,
including people who inject drugs (PWID) and their sexual
partners [3]. Emerging HIV epidemics have been recently doc-
umented among PWID in one-third of MENA countries, with
a risk environment suggesting potential for further HIV spread
[4,5]. As a central population to the epidemic in several coun-
tries [4], PWID are a priority population if the Fast-Track tar-
gets are to be achieved in this region [2].
PWID remain, globally and overall more so in MENA, one of
the hardest-to-reach and most stigmatized KPs, which impedes
the collection of epidemiological data (both risk group size esti-
mates and biological measures) to track PWID through the HIV
cascade and inform policy [2,6-8]. Despite noticeable progress
in the collection of HIV prevalence data in MENA, HIV incidence
data remain scarce among all populations groups [4]. Among
PWID, only three cohort-type HIV incidence studies have been
conducted; in Afghanistan [9], Pakistan [10] and Iran [11], and
all indicated substantial incidence [4]. Quantifying HIV incidence
among PWID in MENA is urgently needed to provide baseline
data to track progress towards UNAIDS target of reducing the
number of new HIV infections among young people and adults
by 75% by 2020 [2].
In this study, we use mathematical modelling to estimate, at
country-level in MENA, HIV incidence among PWID due to non-
sterile drug injections. We also estimate HIV incidence among
their sexual partners due to heterosexual sex with infected PWID,
and delineate the role of injecting drug use as a driver (that is the
factor behind direct and onward transmission) of the HIV epi-
demic in the population. Our approach is comprehensive and aims
to explore and quantify the different HIV transmission pathways
in the population that are initiated by injecting drug use.
Specific objectives are to estimate: (1) the number of inci-
dent HIV infections among PWID and their sexual partners,
(2) the total number of HIV infections that were acquired
among PWID and their sexual partners since the emergence
of the PWID HIV epidemic, (3) the number of HIV infections
among ex-PWID and their sexual partners, where ex-PWID
are individuals who acquired HIV infection while injecting but
have stopped injecting in the past year, and hence could be
missed by programmes targeting current drug users, and (4)
the impact of select interventions on HIV incidence among
PWID and their sexual partners.
2 | METHODS
This study included seven MENA countries with sufficient epi-
demiological data and a current HIV prevalence ≥1% among
PWID [4]. These are Afghanistan, Egypt, Iran, Libya, Morocco, Pak-
istan and Tunisia. The remaining 16 MENA countries have either
zero or unknown HIV prevalence among PWID [4], and hence
estimations of incidence were not possible in these countries.
2.1 | Description of the model
We adapted the Kwon et al. mathematical model of parenteral
HIV transmission among PWID to estimate HIV incidence [12].
This is a cohort-type model that assumes that sharing of nee-
dles/syringes occurs in groups of specific size, where PWID
share in random order, and where each PWID injects once per
sharing event. HIV transmissions through sharing needles/sy-
ringes can then occur in groups containing an infected person.
The model uses input data on HIV prevalence, number of
times a needle/syringe is reused, and levels of effective syr-
inge cleaning to estimate number of HIV transmissions per
sharing event. The model then estimates HIV incidence in the
total PWID population using data on size of the PWID popula-
tion, frequency of injecting, and levels of sharing. We extended
the model by adjusting for the effect of ART (ART efficacy
and country-specific coverage levels in Tables 1 and 2 respec-
tively) and allowing heterogeneity in injecting risk behaviour.
We also allowed the number of times a needle/syringe is
reused to be a function of the sharing group size (model
structure and equations in Additional file 1).
To account for heterogeneity in risk behaviour, we assumed
that the size of the sharing group in each country follows a
gamma distribution. This is a widely used probability distribu-
tion to model heterogeneity in diverse biological, ecological
and physical phenomena. Since the gamma distribution is right
skewed, it assumes that the majority of the PWID population
share injections in smaller groups whereas a small fraction
shares in larger groups (such as at shooting galleries), as sug-
gested by behavioural and qualitative studies [4,8]. In the
absence of clear data to parameterize this variability in inject-
ing risk behaviour, the parameters of the gamma distribution
were informed by available data on the variability in sexual
risk behaviour and networking, and assumed that the variance
of the gamma distribution is equal to its mean [13].
We extended the model to include onward transmission to
sexual partners of PWID whereby infected PWID may trans-
mit the infection to their heterosexual sex sexual partners
through unprotected sex. The number of incident infections
among sexual partners of PWID was estimated using input
data on the proportion of PWID who had a sexual partner in
the last year, HIV prevalence among PWID and among their
sexual partners, and the annual number of unprotected coital
acts per partnership (Additional file 1).
2.2 | Data sources
The model parameters were based on recent empirical HIV
natural history and epidemiology data (Table 1). Whenever
available, country-specific parameter values were used, as
informed mainly by a recent systematic review of HIV and
PWID in MENA [4]. One example is HIV prevalence data
where we used, for each MENA country, the most recent rep-
resentative HIV prevalence among PWID as identified through
the review [4]. Data from integrated bio-behavioural surveil-
lance surveys were preferred over prevalence data generated
through other convenience cross-sectional studies. National-
level estimates from these studies, when available, were used.
In countries with specific location (such as city-based) preva-
lence measures, the mean HIV prevalence was calculated
across these measures. In four out of the seven countries
included in our study (Afghanistan, Iran, Pakistan and Tunisia),
HIV prevalence data came from multiple cities/provinces, and
in two of these countries (Iran and Pakistan), the studies had
a national coverage with 10 to 16 cities/provinces included [4]
Mumtaz GR et al. Journal of the International AIDS Society 2018, 21:e25102
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25102/full | https://doi.org/10.1002/jia2.25102
2
Table 1. Model assumptions in terms of parameter values
Parameter Value Source
Biological parameters
Transmission probability per unsterile injection 0.007 Systematic review and meta-analysis [39]
and long-term cohort study [40]
Transmission probability per unprotected coital
act (non-commercial)
0.003 Systematic review and meta-analysis [41]
Efficacy of ART in reducing HIV transmission 0.96 Clinical trial of treatment for prevention
and other observational data [42,43]
Effectiveness of ART in reducing HIV
transmission
0.69 Calculated as the product of ART efficacy
and adherence
Epidemiology parameters
Total number of PWID See Table 2 MENA PWID data [4,44-48]
ART coverage See Table 2 UNAIDS country estimates for ART
coverage among all people living with
HIV/AIDS in 2015 [49]
HIV prevalence among PWID See Table 2 MENA PWID data [4]
HIV prevalence among sexual partners One-third of HIV prevalence in PWID Bio-behavioural survey in Iran [50],
consistent with similar modelling work
in the region [29]
Natural history parameters
Natural mortality rate per year 0.020 Cohort studies [51,52]
HIV disease mortality rate per year 0.091 UNAIDS data compilation [53] and
cohort studies [54-56]
Behavioural parameters
Adherence of PWID to ART 0.72 Systematic review and meta-analysis [57]
Stopping injection rate per year Lib: 0.04
All countries: 0.10
MENA PWID data [4]
Number of years of injecting after
seroconversion
Lib: 6.8 years
All countries: 4.7 years
Estimated from the natural mortality
rate, HIV disease mortality rate and
stopping injection rate
Average size of sharing group (# of sharing
partners)
Ira: 3, Pak: 2, Others: 3 Iran and Pakistan: model fitting to
epidemiological data
Others: informed by Iran and Pakistan
fitted values and epidemiological data
from Iran [22,23]
Proportion of PWID who inject daily 0.50 Global survey data [12,58]
Number of injections per PWID per day
among those who inject daily
Ira: 3.3, Pak: 2.2, Others: 2.2 Iran and Pakistan: country-specific
epidemiological data [4]
Others: median of all MENA measures
[4]
Average time between two subsequent
injections for PWID who inject less
frequently than daily
14 days Global survey data [12]
Average frequency of injecting per PWID per
year
Ira: 602, Pak: 402, Others: 402 Calculated as a weighted average of daily
and non-daily injectors [12]
Proportion of PWID who share injections Afg: 0.29, Egy: 0.40, Ira: 0.31, Lib: 0.45,
Mor: 0.35, Pak: 0.60, Tun: 0.30
MENA PWID data [4]
Proportion of the injections that are shared for
PWID who share injections
Egy: 0.62, Ira: 0.28, Mor: 0.52, Pak:
0.40, others: 0.40
Egypt, Iran and Pakistan: country-specific
epidemiological data [4]
Others: calculated using other MENA
measures [4]
Average number of times a shared needle/syringe
is used before disposal
Equal to the size of the sharing group,
with a maximum value of 10
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(Table 2). Libya is the only country where a high quality inte-
grated bio-behavioiral survey was conducted in only one city,
Tripoli, whereas two cities contributed to the prevalence in
Egypt and Morocco [4] (Table 2).
Country-specific parameter values were complemented by
global and MENA-wide aggregate data [4], as needed
(Table 1). Model fitting was used to derive one parameter, the
average size of the sharing group (mean of the gamma distri-
bution). We used a deterministic compartmental model [14] to
fit the trend in HIV prevalence in two countries with sufficient
trend data (Iran and Pakistan) [4], and then used the esti-
mated incidence rate and the adapted Kwon et al. model to fit
the value of the sharing group size (Table 1). Fitting was
implemented by minimizing the residual sum of squares
between all data points and model predictions [15].
2.3 | Plan of analysis
We conducted, in each of the seven countries included, the
following estimations that capture the different HIV transmis-
sion pathways arising from injecting drug use in the popula-
tion (Figure 1A). They include estimations of incident and/or
prevalent infections among PWID, ex-PWID, and sexual part-
ners of infected current and ex-PWID. We estimated inci-
dence due to heterosexual sex between infected PWID and
their partners. HIV incidence was defined as the number of
new infections per year, and incidence rate the number of new
infections per susceptible person per year.
2.3.1 | Current year estimations
The model was applied at country-level to estimate HIV inci-
dence and rate among PWID for the current year. Estimated
incidence among PWID was compared to the number of
incident HIV infections in the total population as estimated by
UNAIDS Spectrum model [16]. The number of incident infec-
tions among sexual partners of PWID and of ex-PWID living
with HIV for the current year was estimated. Separate param-
eterization and estimations were made for regular and non-
regular sexual partners, with their sum reported in the results.
2.3.2 | Analysis of past infections
We estimated the number of HIV infections that have ever
been acquired among PWID in each country (past infections;
that is infections that occurred before the current year) by
retracing the course of the HIV epidemic among PWID start-
ing from the year of epidemic emergence, informed by epi-
demiological data [4] (Table 2). We started with 1% HIV
prevalence among PWID at the start of the epidemic HIV
transmission and, in each country, ran the model the number
of times equal to years since HIV epidemic emergence. HIV
prevalence in each year was recalculated by adding the num-
ber of incident infections in this year to the number of preva-
lent infections from previous years, while adjusting for PWID
who (a) stopped injecting, or (b) died from “natural” mortality
(all causes, including overdose), or (c) died from HIV disease
mortality.
Iterating this process over time provides an estimate for
HIV prevalence in the last year. As the observed HIV preva-
lence tended to be higher than the estimated prevalence in
the last year, we increased the level of risk behaviour in the
first iteration, accounting for higher risk behaviour in earlier
years of the epidemic, and used linear interpolation to reach
observed HIV prevalence levels at the last year. A sensitivity
analysis was conducted in one country, Iran, assuming an
exponential, rather than linear, decrease in injecting risk beha-
viour over time. In Libya, the measured HIV prevalence (87%
Table 1. (Continued)
Parameter Value Source
Proportion of PWID with regular sexual partners
in the last year
0.660 MENA PWID data [4]
Proportion of PWID with non-regular sexual
partners in the last year
0.337 MENA PWID data [4]
Number of yearly coital acts with regular sexual
partners
50 Bio-behavioral survey in Iran [50]
Number of yearly coital acts with non-regular
sexual partners
20 Bio-behavioral survey in Iran [50]
Condom use with regular sexual partners
in the last act
0.295 MENA PWID data [4]
Condom use with non-regular sexual partners
in the last act
0.359 MENA PWID data [4]
Needle/syringe cleaning parameters
Effectiveness of needle/syringe cleaning 0.75 Modelling work [12] based on [59] and
[60]
Proportion of shared injections that are cleaned 0.15 MENA PWID data [4], & modelling work
[61] based on [62]
Afg, Afghanistan; ART, antiretroviral therapy; Egy, Egypt; Ira, Iran; Lib, Libya; MENA, Middle East and North Africa; Mor, Morocco; Pak, Pakistan;
PWID, people who inject drugs; Tun, Tunisia.
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[17]) was not consistent with reported levels of current risk
behaviour and hence, estimations of past exposures were not
possible.
The past infections model was also used to estimate the
number of incident cases that ever happened among sexual
partners of infected current and ex-PWID since HIV epidemic
emergence. The prevalent number of infected current/ex-
PWID, and their partners were estimated.
2.3.3 | Uncertainty analysis
Multivariate uncertainty analysis was conducted to specify the
range of uncertainty in the estimated HIV incidence for the
current year among PWID and their sexual partners. Two sets
of uncertainty analyses were conducted, one where model
parameters were varied within 25% of their point estimates,
as a reasonable variation based on existing similar modelling
studies [18,19], and another more conservative analysis with
50% variation around model parameters values. In both, HIV
prevalence was varied within its measured 95% confidence
interval (Table 2). We implemented 10,000 runs using Monte
Carlo sampling from uniform probability distributions for the
uncertainty in parameters. 95% uncertainty intervals (UI) for
the estimates were determined.
2.3.4 | Impact of interventions
We examined the effect of select interventions targeted at
PWID: (1) Reducing current sharing of needles/syringes by
25%, 50%, and 75% on HIV incidence among PWID, (2) Intro-
ducing opioid substitution therapy (OST) resulting in 10%
reduction in the number of PWID and a 10%, 20%, or 30%
reduction in the frequency of injecting, on HIV incidence
among PWID, (3) Expanding ART coverage among PWID
based on most recent test-and-treat World Health Organiza-
tion (WHO) guidelines [20,21] to reach coverage levels of
25%, 50%, and the global target of 81% [3], on HIV incidence
among PWID and their sexual partners, and (4) Increasing
current condom use by 25%, 50%, and 75% on HIV incidence
among sexual partners. Of note, that the impact of ART is
dependent on adherence and existing coverage levels in each
country.
We also examined the impact of two packages that include
a combination of the above-mentioned interventions. These
packages bracket the realm of plausibility for interventions
within the MENA context and have been reached, at least in
part, in other regions, such as the impressive scale-up of ART
in resource-limited settings in sub-Saharan Africa. The less
optimistic scenario includes reducing sharing by 25%, reducing
the number of PWID by 10% and the frequency of injecting
by 10% (effect of OST), increasing ART coverage to 50%, and
increasing condom use by 25%. The more optimistic scenario
includes reducing sharing by 75%, reducing the number of
PWID by 10% and the frequency of injecting by 30%, increas-
ing ART coverage to 81%, and increasing condom use by 75%.
3 | RESULTS
The size of the sharing group as estimated through model fit-
ting was two in Pakistan and three in Iran (Table 1). We usedTa
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a sharing group size of three for the remaining countries, as a
rounded-up average of our estimates in Pakistan and Iran. This
sharing group size is in line with both, the global literature
[12] and behavioural data from MENA [22,23].
Results of all main estimations of HIV incidence among
PWID and their sexual partners are in Table 2. Table 2 fea-
tures also results of the uncertainty analysis with 25% varia-
tion around model parameters, whereas the impact of a 50%
variation on our estimations can be found in Additional File 1,
Table 2. The estimated incidence rate among PWID was low-
est in Tunisia and Afghanistan at 0.7% (95% UI: 0.4% to 1.4%)
and 1.2% (95% UI: 0.8% to 2.4%) per person-year (ppy)
respectively, and highest in Pakistan at 7.8% ppy (95% UI:
4.3% to 13.4%). Libya, at an HIV prevalence of 87% among
PWID [17], was an outlier with an estimated incidence rate of
24.8% ppy (95% UI: 13.3% to 41.3%). The incidence rate in
remaining countries was around 4% ppy. The estimated num-
ber of incident infections for the current year was lowest in
Tunisia (n = 79) and Morocco (n = 99), and highest in Iran
and Pakistan (around 6700 each). These PWID incident infec-
tions represent over 90% of all incident cases in the total
population in Iran, 39% in Pakistan, 16% to 21% in Tunisia
and Afghanistan, and 8% in Morocco. In addition, 20 to 2208
and 5 to 837 new infections were estimated at country-level
among sexual partners of current and ex-PWID for this year
respectively (Table 2).
In total, we estimated that about 82,000 to 90,000 infec-
tions happened among PWID since the start of the PWID
HIV epidemic in Iran and Pakistan each; over 12,250 hap-
pened in Egypt; 1753 happened in Afghanistan; and over
760 happened in Morocco and Tunisia each (Table 2). Simi-
larly, up to 18,244 and 4360 HIV infections were among
sexual partners of current and ex-PWID respectively, in each
of Iran and Pakistan since the start of the PWID HIV epi-
demic. After accounting for stopping injection and mortality,
we estimated that there are currently, at country-level, 347
to 32,279 prevalent HIV infections among current PWID,
119 to 16,540 among ex-PWID, and 67 to 10,752 and 12
to 2863 among sexual partners of current and ex-PWID
respectively. The lowest numbers of prevalent infections
were in Morocco and Tunisia, while the highest were in Iran
and Pakistan (Table 2). Sensitivity analysis indicated a minor
impact of the change in the distribution of injecting risk
behaviour over the course of the HIV epidemic on these
findings (Additional File, Table 3).
The impact of interventions on HIV incidence among PWID
and/or their sexual partners is in Table 3 and Figures 2 and
3. Reducing sharing by 25%, 50% and 75% respectively was
associated with a similar proportional reduction in the number
of incident infections among PWID. Reducing sharing by 25%
would avert 20 to 53 infections per year in Afghanistan, Libya,
Morocco and Tunisia; over 800 infections in Egypt; and about
1700 infections in Iran and Pakistan each. A reduction in shar-
ing by 75% would avert over 5000 infections per year in each
of Iran and Pakistan (Table 3).
Introducing OST programmes with various coverage levels
was found to lead to 19% to 37% reduction in the number of
incident infections among PWID. A reduction in injecting fre-
quency by 30% and in the number of PWID by 10%, as a
result of OST, would avert up to 80 infections per year in
Figure 1. HIV transmission pathways in the population arising from injecting drug use. Panel (A) displays the various HIV transmission path-
ways that are due to injecting drug use, starting among people who inject drugs (PWID) and percolation of infection to the wider non-inject-
ing community – mainly sexual partners of current and ex-PWID. The blue oval refers to the PWID population, while the white space
around it refers to the general population. Black arrows refer to transmission chains. Panels (B) and (C) provide one example from Pakistan
for the number of incident (B) and prevalent (C) infections that are caused by these transmission pathways and that affect the different
members of the injecting and non-injecting communities.
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Afghanistan, Libya, Morocco and Tunisia; over 1100 infections
in Egypt; and about 2500 infections in each of Iran and Pak-
istan (Table 3).
Increasing ART coverage to 25%, 50% and 81% of all
infected PWID would reduce incidence among PWID and
their sexual partners at country-level by 5% to 14%, 12% to
32% and 40% to 54% respectively (Table 3, Figure 2). In all
seven countries combined, 50% ART coverage would result in
5100 and 1400 infections averted per year among PWID and
their sexual partners respectively (Figure 2). Increasing con-
dom use by 25%, 50% and 75% would result in 11%, 21%
and 32% reduction in the number of annual infections among
sexual partners of PWID (Table 3).
Finally, implementing the less optimistic intervention pack-
age would avert 57% (n = 40 to 3906 at country-level) and
43% (n = 6 to 978) of incident infections per year among
PWID and their sexual partners respectively, while the more
optimistic scenario would avert 93% (n = 73 to 6272) and
71% (n = 13 to 1576) of these infections respectively
(Table 3, Figure 3).
4 | DISCUSSION
A relatively high HIV incidence rate among PWID was found
in most MENA countries with at least 1% prevalence among
PWID (range: 4% to 8% ppy), supporting recent analyses indi-
cating concentrated and at times rapidly growing HIV epi-
demics among PWID [4]. A lower incidence rate of about 1%
ppy was estimated in Afghanistan, where epidemiological data
points to a nascent localized HIV epidemic among PWID [4],
and in Tunisia where the PWID HIV epidemic appears to be
at low level [4]. Libya stood out with an estimated incidence
rate of 25% ppy. This reflects the very high 87% HIV preva-
lence among PWID found in the best study in this country –
one of the highest prevalence ever reported among PWID
Table 3. Number and proportion of HIV infections averted due to select interventions in comparison with baseline (current year)
estimations of incidence among people who inject drugs and their heterosexual sex partners in the Middle East and North Africa
Afghanistan Egypt Iran Libya Morocco Pakistan Tunisia
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
People who inject drugs
Reducing sharing needles/syringes by 25% 53 (25) 804 (25) 1693 (25) 36 (25) 25 (25) 1670 (25) 20 (25)
Reducing sharing needles/syringes by 50% 107 (50) 1608 (50) 3386 (50) 71 (50) 49 (50) 3340 (50) 40 (50)
Reducing sharing needles/syringes by 75% 160 (75) 2412 (75) 5080 (75) 107 (75) 74 (75) 5009 (75) 60 (75)
Impact of OST:
Reducing the number of PWID by 10% and:
reducing injecting frequency by 10% 40 (19) 611 (19) 1287 (19) 27 (19) 19 (19) 1269 (19) 15 (19)
reducing injecting frequency by 20% 60 (28) 901 (28) 1869 (28) 40 (28) 28 (28) 1870 (28) 22 (28)
reducing injecting frequency by 30% 79 (37) 1190 (37) 2506 (37) 53 (37) 37 (37) 2471 (37) 29 (37)
Increasing ART coverage among PWID to 25% 30 (14) 161 (50) 810 (12.0) 9 (6.5) NAa 909 (13.6) NAa
Increasing ART coverage to 50% 68 (32) 798 (24) 2053 (30) 37 (26) 12 (12) 2112 (32) 15 (19)
Increasing ART coverage to 81% 116 (54) 1588 (49) 3595 (53) 71 (50) 40 (41) 3604 (54) 36 (45)
Intervention packages:
Less optimistic scenariob 125 (59) 1747 (54) 3906 (58) 78 (55) 46 (47) 3905 (58) 40 (51)
More optimistic scenarioc 198 (93) 2960 (92) 6272 (93) 131 (92) 90 (91) 6195 (93) 73 (91)
Sexual partners
Increasing ART coverage to 25% 8 (14) 21 (5) 228 (12) 12 (6) NAa 289 (13) NAa
Increasing ART coverage to 50% 19 (31) 106 (24) 581 (29) 49 (25) 2 (12) 677 (31) 4 (18)
Increasing ART coverage to 81% 33 (53) 214 (48) 1028 (52) 95 (49) 8 (40) 1167 (53) 10 (44)
Increasing condom use by 25% 7 (11) 47 (11) 210 (11) 21 (11) 2 (11) 234 (11) 2 (11)
Increasing condom use by 50% 13 (21) 94 (21) 421 (21) 41 (21) 4 (21) 470 (21) 5 (21)
Increasing condom use by 75% 20 (32) 142 (32) 635 (32) 62 (32) 6 (32) 709 (32) 7 (32)
Intervention packages:
Less optimistic scenariob 28 (45) 172 (39) 856 (43) 77 (40) 6 (29) 978 (44) 7 (34)
More optimistic scenarioc 45 (72) 304 (69) 1401 (71) 134 (69) 13 (64) 1576 (71) 14 (66)
ART, antiretroviral therapy; OST, opioid substitution therapy; PWID, people who inject drugs.
The effectiveness of ART in reducing HIV transmission is non-optimal due to adherence issues among PWID (Table 1).
aBaseline ART coverage is greater than 25%.
bReducing sharing needles/syringes by 25%, reducing the number of PWID by 10% and reducing injecting frequency by 10%, increasing ART cov-
erage to 50%, and increasing condom use by 25%.
cReducing sharing needles/syringes by 75%, reducing the number of PWID by 10% and reducing injecting frequency by 30%, increasing ART cov-
erage to 81%, and increasing condom use by 75%.
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Figure 2. Effect of expanding antiretroviral therapy coverage (ART) on HIV incidence among people who inject drugs (PWID) and their
heterosexual sex partners in the Middle East and North Africa (MENA). The graphs display, at various ART coverage levels, the number of
new HIV infections and the number of infections averted in comparison with baseline (current year) estimations of HIV incidence among
PWID and their heterosexual sex partners.
Figure 3. Effect of two comprehensive intervention packages on HIV incidence among people who inject drugs (PWID) (A) and their hetero-
sexual sex partners (B) in all seven Middle East and North Africa (MENA) countries. The package with the less optimistic scenario includes
reducing sharing by 25%, reducing the number of PWID by 10% and reducing injecting frequency by 10% (effect of opioid substitution ther-
apy), increasing ART coverage to 50%, and increasing condom use by 25%. The package with the more optimistic scenario includes reducing
sharing by 75%, reducing the number of PWID by 10% and reducing injecting frequency by 30%, increasing ART coverage to 81%, and
increasing condom use by 75%. The graphs display the number of new HIV infections and the number of infections averted in comparison
with baseline (current year) estimations of HIV incidence among PWID and their heterosexual sex partners.
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globally, a figure difficult to interpret and generalize for all of
Libya in view of the limited data in this country [4,17].
Our estimates of HIV incidence among PWID are overall
consistent with our epidemiological understanding of the HIV
epidemic among PWID in each country [4], and are congruent
with the estimated size of the epidemic in the whole popula-
tion per UNAIDS Spectrum estimates [16]. For example,
PWID contributed the vast majority of HIV infections in Iran,
a country with an established HIV epidemic among PWID
[4,5,14] and where injecting drug use is the main driver of the
epidemic at the national level [4,24]. Similarly, a small contri-
bution of PWID to total incidence was found in Tunisia and
Morocco; two countries where the HIV epidemic is mainly
focused among men who have sex with men (MSM) and com-
mercial sex networks respectively [25-29].
We also found that a substantial number of HIV infections
in the general population are linked to infections among
PWID, due to individuals who acquired the infection in the
past through drug injection, but are no longer injecting, and
due to onward transmission to sexual partners. We estimated
that about 30% of incident HIV infections that are due to
injecting drug use are among sexual partners of current/ex-
PWID, and about half of prevalent infections are among ex-
PWID and sexual partners of current/ex-PWID (Figure 1B
and C). Figure 1 highlights how injecting drug use drives HIV
transmission not only among current PWID but also among
individuals with no or no recent injecting drug use. Our find-
ings agree with recent Mode of Transmission analyses in the
region that estimated a substantial number of HIV infections
among sexual partners/spouses of persons engaging in HIV
high-risk behaviour such as PWID, clients of female sex work-
ers and MSM [24,27,29].
Despite the growing epidemics among PWID, the HIV
response remains limited in MENA. By 2014, needle and syr-
inge exchange programmes (NSP) were available in nine
countries, and OST in five [30]. MENA has the lowest ART
coverage globally at a median of 17% in 2015 [31], and could
not reach the 2015 mid-term regional objective of 50% cov-
erage under WHO’s initiative to end MENA’s HIV treatment
crisis [32]. The treatment cascade among PWID seems to
suggest an even harsher reality [33]. The striking gap
between regional figures and the 90-90-90 target is of great
concern, especially since the epidemic in this region is
strongly driven by injecting drug use. The punitive legal envi-
ronment, stigma around HIV testing, and fear of discrimina-
tion are all challenges that hamper uptake of treatment by
PWID [3]. These challenges need to be addressed to scale-up
testing, access to ART, and retention in care. We estimated
that increasing ART coverage to the global target of 81%
(90% of 90%), would alone avert close to half of incident
infections among PWID and their sexual partners. Combining
ART scale-up with harm reduction – including NSP, OST and
condom distribution – as part of an optimistic package would
avert over 90% and 70% of infections among PWID and
their sexual partners respectively (Figure 3). Furthermore
studies and considerations – including a discussion dialogue
with programme managers, NGOs, affected communities, and
other stakeholders – are needed to assess implementation
and coverage of these and other interventions, as well as
potential barriers and challenges within the MENA context,
to reach the desired targets.
There were several limitations in our study. Though we used
an elaborate mathematical model structure, our results may
depend on the model structure used. For example, we did not
account for sexual transmission of HIV among PWID, for anal
sex with same-sex partners, and for further onward transmis-
sion beyond the direct spouses/sexual partners. This implies
that the impact of PWID as drivers of HIV infection in the
population is even larger than what we have estimated with
our model. The model also assumes essentially a static struc-
ture of injecting groups and does not strictly factor in the full
dynamics of partnership formation and dissolution.
Furthermore, estimations were possible in only seven
MENA countries with sufficient epidemiological data indicating
HIV transmission among PWID. In a number of countries,
there are no data about HIV prevalence in PWID, and these
countries were naturally not included in our analysis. In others
such as Lebanon and Jordan, some studies have been con-
ducted but, in the samples collected, there were no HIV-posi-
tive cases. While there might be hidden HIV epidemics among
PWID, or some small background transmission, these were
not captured by available studies. This, however, may also truly
reflect that HIV has not yet been sufficiently introduced to
PWID networks to start epidemic transmission in these coun-
tries.
We also assumed that available HIV bio-behavioural data in
each included country is representative of the epidemic at
national level and also assumed that current HIV prevalence
is the same as most recent representative HIV prevalence.
However, these assumptions are only approximately valid. In
countries where HIV prevalence data came from only a few
geographical localities, our estimates can be biased if these
available data are not representative of HIV prevalence
among PWID at the national level. For example, in Libya, the
HIV prevalence data came from one city, Tripoli [41], and the
scale of the epidemic in other parts of Libya is unknown. Simi-
larly, HIV prevalence in each of Cairo and Alexandria was 7%,
but no other localities in Egypt were covered by the IBBSS
[58]. In Morocco, we used average HIV prevalence of two
cities where studies were conducted, and estimated an inci-
dence rate of 3.7% ppy. Running our model separately in the
two localities generated an incidence of 0.1% ppy in Tanger
and 7.4% ppy in Nador, highlighting the diversity of the epi-
demic within Morocco (data not shown). There is however
solid epidemiological evidence that the HIV PWID epidemic in
both Iran and Pakistan has reached high levels at the national
level [4].
Also, as with all modelling work, the robustness of our find-
ings depends on the quality of input data. While we used the
best-available data in the region, including many quality inte-
grated bio-behavioural surveillance surveys (IBBSS) [4], the
availability and quality of data varied between countries, and
there were no MENA-specific data on some parameters.
Noticeable decrease in Global Fund funding for the conduct
of IBBSS in the region, as well as rising conflicts with compet-
ing national priorities in several countries, have contributed to
some of these data gaps. To accommodate for the uncertainty
in input parameters, we conducted uncertainty analyses with
wide ranges for parameters.
Despite these limitations, this study fills an important gap in
estimating HIV infection levels in MENA. HIV-related esti-
mates in MENA are typically produced through established
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mathematical models applied globally such as UNAIDS Spec-
trum [16] and the Global Burden of Disease (GBD) models
[34]. While these models provide two different approaches for
HIV estimations, their focus is on total population-level esti-
mates [34,35], which may overlook the dynamics of infection
among hidden KPs such as PWID. In this study, we model HIV
transmission specifically among PWID, and use quality input
data derived from this same population. Such ‘microscopic’
approach could potentially offer more realistic estimations,
and may explain some of the inconsistencies observed
between our estimates and those of UNAIDS and GBD. One
example is the lower than expected contribution of PWID to
total incidence we estimated in Afghanistan and Pakistan –
two countries where the epidemic is apparently largely driven
by injecting drug use [4]. In Afghanistan, a similar HIV inci-
dence rate of 1.5% ppy was measured among PWID in a
cohort study [9]. Under-reporting of injecting risk behaviour,
hidden HIV epidemics among PWID in sites not covered by
the IBBSS, and emerging and/or hidden HIV epidemics among
other KPs such as MSM in Pakistan, could be potential expla-
nations to the observed lower contribution of PWID to total
incidence. Another example is the exceeding number of inci-
dent infections we estimated among PWID in Egypt compared
to UNAIDS estimated total number of infections in the popu-
lation, which could be due to the fact that the concentrated
HIV epidemic among PWID may be limited to the two cities
where the IBBSS studies were conducted. Careful triangula-
tion of multiple sources of evidence is needed to alleviate
some of these apparent contradictions, which in truth may
reflect incomplete understanding of HIV epidemiology [25].
In addition to providing estimates of incidence, our study
provided insights into HIV epidemic dynamics among PWID.
Our analyses indicated that current levels of injecting risk
behaviour could not explain observed prevalence nor the
speed at which these epidemics rose. While it could be par-
tially due to underreporting of risk behaviour, this suggests
that the epidemic was initially spreading among PWID sub-
groups with higher levels of risk behaviour. These findings
agree with the contextual understanding of these epidemics.
For example, the HIV PWID epidemics in Iran and Pakistan
started in prisons [36], where they were ignited by limited
access to clean needles/syringes and considerable levels of
sharing. In Iran, there are reports of syringes being reused 30
to 40 times in prisons [37], with one study measuring a very
high HIV incidence rate of 17.2% ppy among incarcerated
PWID in a Tehran prison in 2002 [11]. In Libya, assuming
even extreme levels of risk behaviour at epidemic onset could
not retrace the course of the epidemic. Since PWID have rela-
tively short injecting careers and high turnover, it is difficult
to understand how HIV prevalence has reached such high
level. Possibly, this may reflect a very recent HIV sub-epidemic
among the PWID group that was sampled in Tripoli.
5 | CONCLUSION
We estimated substantial HIV incidence among PWID in
MENA. This is mainly because some of the largest countries,
such as Iran and Pakistan, are affected by HIV PWID epi-
demics with high HIV prevalence. In several countries, PWID
were found to contribute dominantly to HIV incidence.
Concerted efforts are needed to bypass persistent barriers
from governments, society, and health systems to improve
service delivery to PWID and their retention throughout the
cascade [6]. Comprehensive programmes that include ART,
NSP, OST, voluntary testing and counselling, and prevention of
sexually transmitted infections should be established and
extended to include settings of vulnerability such as prisons
[38].
We further estimated that for each currently infected
PWID there is one other HIV-infected person in the general
population who acquired the infection through PWID dynam-
ics, either as an ex-PWID or as a sexual partner of current/
ex-PWID (Figure 1). Innovative, context-sensitive approaches
are needed to reach these populations who are usually
missed by programmes targeted at PWID, and a large frac-
tion of whom are women, for appropriate interventions and
linkage to care.
HIV surveillance among PWID must be expanded in MENA,
mainly through the conduct of repeated rounds of IBBSS.
Inclusion of sexual partners of PWID should be considered, as
well as population size estimations. Generating such epidemio-
logical data will help monitor HIV epidemics, improve quality
of input data for estimation studies, guide policy and pro-
grammes, and track PWID through the HIV treatment cas-
cade.
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